Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EmpaSound trial of empasiprubart in multifocal motor neuropathy
NL-OMON61788Phase 1Not yet recruiting
- Sponsor
- argenx
- Start
- Nov 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of empasiprubart in multifocal motor neuropathy (MMN), sponsored by argenx. Primary endpoint: Change from baseline in nerve cross-sectional area at week 24. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
empasiprubart
03
Conditions
multifocal motor neuropathy (MMN)
Beyond the preview
Go deeper on NL-OMON61788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61788.